Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
Authors
Keywords
-
Journal
OncoImmunology
Volume 2, Issue 1, Pages e22890
Publisher
Informa UK Limited
Online
2013-01-10
DOI
10.4161/onci.22890
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- (2012) Richard C. Koya et al. CANCER RESEARCH
- MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells
- (2012) Cristina Garrido et al. CARCINOGENESIS
- Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation
- (2012) J. Kline et al. JOURNAL OF IMMUNOLOGY
- BRAF inhibition improves tumor recognition by the immune system
- (2012) Marco Donia et al. OncoImmunology
- EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?
- (2012) Brian P. Pollack OncoImmunology
- Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
- (2011) L Sigalotti et al. BRITISH JOURNAL OF CANCER
- Combination of targeted therapy and immunotherapy in melanoma
- (2011) Christian U. Blank et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
- (2011) B. P. Pollack et al. CLINICAL CANCER RESEARCH
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- The Two Faces of Interferon- in Cancer
- (2011) M. R. Zaidi et al. CLINICAL CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Strategies to counteract MHC-I defects in tumors
- (2011) Margit H Lampen et al. CURRENT OPINION IN IMMUNOLOGY
- Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes
- (2011) Rafael Carretero et al. INTERNATIONAL JOURNAL OF CANCER
- Immunotherapy for metastatic melanoma
- (2011) Christopher R. Zito et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- GILT Modulates CD4+ T-Cell Tolerance to the Melanocyte Differentiation Antigen Tyrosinase-Related Protein 1
- (2011) Matthew P. Rausch et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Melanoma survival in the United States, 1992 to 2005
- (2011) Lori A. Pollack et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
- (2011) Douglas J. Schwartzentruber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
- (2010) B. Comin-Anduix et al. CLINICAL CANCER RESEARCH
- Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
- (2010) Jill C Rubinstein et al. Journal of Translational Medicine
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- NLR family member NLRC5 is a transcriptional regulator of MHC class I genes
- (2010) T. B. Meissner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma
- (2009) SubbaRao V. Madhunapantula et al. Pigment Cell & Melanoma Research
- Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy
- (2008) Rafael Carretero et al. IMMUNOGENETICS
- BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells
- (2008) E. Sala et al. MOLECULAR CANCER RESEARCH
- Ultraviolet Radiation-induced Transcription is Associated with Gene-specific Histone Acetylation
- (2008) Brian P. Pollack et al. PHOTOCHEMISTRY AND PHOTOBIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started